Prognostic Value of Mature MicroRNA-21 and MicroRNA-205 Overexpression in Non–Small Cell Lung Cancer by Quantitative Real-Time RT-PCR

Markou, Athina; Tsaroucha, Emily; Kaklamanis, Loukas; Fotinou, Marianthi; Georgoulias, Vassilis; Lianidou, Evi

doi:10.1373/clinchem.2007.101741

Cited by 401 publications

(279 citation statements)

References 38 publications

(43 reference statements)

Supporting

Mentioning

251

Contrasting

Unclassified

Order By: Relevance

“…Whereas other groups have found that hsa-miR-21 was prognostic in breast 31 and nonsmall cell lung cancer, 24 and hsa-miR-10b to be prognostic in breast cancer, 18 we did not find either hsamiR-21 or hsa-miR-10b to be prognostic in HNSCC. hsa-miR-210 remained prognostic, even after adjusting for the other variables 1 at a time in a Cox model, and performed favorably as a prognostic marker in comparison to other markers of hypoxia such as the HIF target genes CA9 and TWIST.…”

Section: Discussioncontrasting

confidence: 99%

See 1 more Smart Citation

hsa‐miR‐210 is a marker of tumor hypoxia and a prognostic factor in head and neck cancer

Gee

Camps

Buffa

et al. 2010

Cancer

186

154

View full text Add to dashboard Cite

BACKGROUND:Hypoxia is an important mechanism of treatment resistance in head and neck squamous cell carcinoma (HNSCC). MicroRNAs are short noncoding RNAs that regulate multiple mRNAs and are frequently dysregulated in cancer. The authors have investigated the role of 3 microRNAs, including the hypoxia-induced hsa-miR-210, as potential markers of hypoxia or prognosis. METHODS: Three hypoxia-related microRNAs, hsa-miR-210, hsa-miR-21, and hsa-miR-10b, were measured in 46 samples from patients with HNSCC. Expression levels were correlated with clinicopathological variables and other markers of hypoxia: a published 99-gene hypoxia metagene, individual hypoxia-related genes such as TWIST1, and immunohistochemical expression of hypoxia-inducible factor 1 and its target gene carbonic anhydrase 9. We then performed survival analyses to investigate the prognostic significance of these microRNAs. RESULTS: Only the level of hsa-miR-210 was significantly correlated with other markers of hypoxia, including the 99-gene hypoxia metagene (rho ¼ 0.67, P < .001). We found no association between hsa-miR-210, hsamiR-21, or hsa-miR-10b and clinicopathological variables such as tumor size, differentiation, and stage. However, high levels of hsa-miR-210 were associated with locoregional disease recurrence (P ¼ .001) and short overall survival (P ¼ .008). hsa-miR-21 and hsa-miR-10b had no prognostic significance. CONCLUSIONS: Expression of hsa-miR-210 in head and neck cancer correlates with other approaches for assessing hypoxia and is associated with prognosis. This warrants further study as a classification marker of patients for therapies involving modulation of hypoxia.

show abstract

Section: Discussioncontrasting

confidence: 99%

“…21 hsa-miR-21 is overexpressed in many cancers, including HNSCC, 22,23 and is associated with a poor prognosis in nonsmall cell lung cancer. 24 Its targets include the tumor suppressors phosphatase and tensin homolog, 25 tropomysin 1, 26 and programmed cell death 4. 27 hsa-miR-21 was shown to be hypoxia-induced in breast cancer cell lines.…”

mentioning

confidence: 99%

hsa‐miR‐210 is a marker of tumor hypoxia and a prognostic factor in head and neck cancer

Gee

Camps

Buffa

et al. 2010

Cancer

186

154

View full text Add to dashboard Cite

show abstract

“…This is the first evidence of a causal effect of Ras oncogenic activation on the induction of miR-21 in vivo. We analyzed miR-21 expression in human lung cancers and demonstrated that it is overexpressed in the majority of cases, accordingly to already reported data (Lu et al, 2005;Volinia et al, 2006;Yanaihara et al, 2006;Markou et al, 2008). In our collection, however, we found significantly higher levels of miR-21 in early-stage tumors.…”

Section: Discussionsupporting

confidence: 67%

Upregulation of miR-21 by Ras in vivo and its role in tumor growth

et al. 2010

View full text Add to dashboard Cite

miR-21 is a microRNA (miRNA) frequently overexpressed in human cancers. Here we show that miR-21 is upregulated both in vitro and in vivo by oncogenic Ras, thus linking this miRNA to one of the most frequently activated oncogenes in human cancers. Ras regulation of miR-21 occurs with a delayed kinetic and requires at least two Ras downstream pathways. A screen of human thyroid cancers and non-small-cell lung cancers for the expression of miR-21 reveals that it is overexpressed mainly in anaplastic thyroid carcinomas, the most aggressive form of thyroid cancer, whereas in lung its overexpression appears to be inversely correlated with tumor progression. We also show that a LNA directed against miR-21 slows down tumor growth in mice. Consistently, a search for mRNAs downregulated by miR-21 shows an enrichment for mRNAs encoding cell cycle checkpoints regulators, suggesting an important role for miR-21 in oncogenic Ras-induced cell proliferation.

show abstract

“…Its functions in cancer appear to be tissue type specific. MiR-205 expression level is reportedly upregulated in human samples of lung cancer, 69 bladder cancer, 70 and endometrioid adenocarcinoma, 71 and downregulated in breast cancer, [72][73][74] prostate cancer, 75 and melanoma. 76 It has been reported that in a cohort of early breast cancer patients, decreased miR-205 is associated with worse disease-free interval and overall survival.…”

Section: Discussionmentioning

confidence: 99%

MicroRNA expression profiling identifies decreased expression of miR-205 in inflammatory breast cancer

et al. 2016

View full text Add to dashboard Cite

Inflammatory breast cancer is the most aggressive form of breast cancer. Identifying new biomarkers to be used as therapeutic targets is in urgent need. Messenger RNA expression profiling studies have indicated that inflammatory breast cancer is a transcriptionally heterogeneous disease, and specific molecular targets for inflammatory breast cancer have not been well established. We performed microRNA expression profiling in inflammatory breast cancer in comparison with locally advanced noninflammatory breast cancer in this study. Although many microRNAs were differentially expressed between normal breast tissue and tumor tissue, most of them did not show differential expression between inflammatory and noninflammatory tumor samples. However, by microarray analysis, quantitative reverse transcription PCR, and in situ hybridization, we showed that microRNA-205 expression was decreased not only in tumor compared with normal breast tissue, but also in inflammatory breast cancer compared with noninflammatory breast cancer. Lower expression of microRNA-205 correlated with worse distant metastasis-free survival and overall survival in our cohort. A small-scale immunohistochemistry analysis showed coexistence of decreased microRNA-205 expression and decreased E-cadherin expression in some ductal tumors. MicroRNA-205 may serve as a therapeutic target in advanced breast cancer including inflammatory breast cancer.

show abstract

Prognostic Value of Mature MicroRNA-21 and MicroRNA-205 Overexpression in Non–Small Cell Lung Cancer by Quantitative Real-Time RT-PCR

Abstract: BACKGROUND: microRNA (miRNA) expression profiles are being intensively investigated for their involvement in carcinogenesis. We evaluated the prognostic value of mature microRNA-21 (miR-21) and mature microRNA-205 (miR-205) overexpression in non-small cell lung cancer (NSCLC).

Cited by 401 publications

References 38 publications

hsa‐miR‐210 is a marker of tumor hypoxia and a prognostic factor in head and neck cancer

hsa‐miR‐210 is a marker of tumor hypoxia and a prognostic factor in head and neck cancer

Upregulation of miR-21 by Ras in vivo and its role in tumor growth

MicroRNA expression profiling identifies decreased expression of miR-205 in inflammatory breast cancer

Contact Info

Product

Resources

About